» Articles » PMID: 38807595

RNA MC Methylation: a Potential Modulator of Innate Immune Pathways in Hepatocellular Carcinoma

Overview
Journal Front Immunol
Date 2024 May 29
PMID 38807595
Authors
Affiliations
Soon will be listed here.
Abstract

RNA 5-methylcytosine (mC) methylation plays a crucial role in hepatocellular carcinoma (HCC). As reported, aberrant mC methylation is closely associated with the progression, therapeutic efficacy, and prognosis of HCC. The innate immune system functions as the primary defense mechanism in the body against pathogenic infections and tumors since it can activate innate immune pathways through pattern recognition receptors to exert anti-infection and anti-tumor effects. Recently, mC methylation has been demonstrated to affect the activation of innate immune pathways including TLR, cGAS-STING, and RIG-I pathways by modulating RNA function, unveiling new mechanisms underlying the regulation of innate immune responses by tumor cells. However, research on mC methylation and its interplay with innate immune pathways is still in its infancy. Therefore, this review details the biological significance of RNA mC methylation in HCC and discusses its potential regulatory relationship with TLR, cGAS-STING, and RIG-I pathways, thereby providing fresh insights into the role of RNA methylation in the innate immune mechanisms and treatment of HCC.

Citing Articles

Biological functions of 5-methylcytosine RNA-binding proteins and their potential mechanisms in human cancers.

Zhao T, Zhang Z, Chen Z, Xu G, Wang Y, Wang F Front Oncol. 2025; 15:1534948.

PMID: 39990690 PMC: 11842269. DOI: 10.3389/fonc.2025.1534948.


m5C methylation modification may be an accomplice in colorectal cancer escaping from anti-tumor effects of innate immunity-type I/III interferon.

Sun Y, Liu Y, Jiang L, Zhong C Front Immunol. 2025; 15:1512353.

PMID: 39867908 PMC: 11757137. DOI: 10.3389/fimmu.2024.1512353.


The Quiet Giant: Identification, Effectors, Molecular Mechanism, Physiological and Pathological Function in mRNA 5-methylcytosine Modification.

Wang R, Ding L, Lin Y, Luo W, Xu Z, Li W Int J Biol Sci. 2024; 20(15):6241-6254.

PMID: 39664561 PMC: 11628344. DOI: 10.7150/ijbs.101337.

References
1.
Zhong M, Zhong C, Cui W, Wang G, Zheng G, Li L . Induction of tolerogenic dendritic cells by activated TGF-β/Akt/Smad2 signaling in RIG-I-deficient stemness-high human liver cancer cells. BMC Cancer. 2019; 19(1):439. PMC: 6515680. DOI: 10.1186/s12885-019-5670-9. View

2.
Li K, Gong Y, Qiu D, Tang H, Zhang J, Yuan Z . Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC. J Immunother Cancer. 2022; 10(8). PMC: 9413187. DOI: 10.1136/jitc-2021-004006. View

3.
Ren X, Wang F, Ji B, Gao C . TLR7 agonist induced repression of hepatocellular carcinoma via the TLR7-IKK-NF-κB-IL6 signaling pathway. Oncol Lett. 2016; 11(5):2965-2970. PMC: 4840696. DOI: 10.3892/ol.2016.4329. View

4.
Gu X, Zhou H, Chu Q, Zheng Q, Wang J, Zhu H . Uncovering the Association Between mC Regulator-Mediated Methylation Modification Patterns and Tumour Microenvironment Infiltration Characteristics in Hepatocellular Carcinoma. Front Cell Dev Biol. 2021; 9:727935. PMC: 8475949. DOI: 10.3389/fcell.2021.727935. View

5.
Kariko K, Buckstein M, Ni H, Weissman D . Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005; 23(2):165-75. DOI: 10.1016/j.immuni.2005.06.008. View